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acid (EKODE), has been described.6 
EKODE stimulates aldosteronogen-
esis at concentrations as low as 0.5 µM. 
EKODE was found to mobilize calcium 
from stores in adrenal glomerulosa cells 
and subsequently to increase aldosterone 
secretion from adrenal cells via inositol 
1,4,5-triphosphate signaling.7 Th is work 
provides an important link between obes-
ity, the metabolic syndrome, and a novel 
stimulus for aldosterone production, inde-
pendent of classical angiotensin II- and 
potassium-dependent pathways. Work 
on novel mechanisms regarding aldoster-
one production and action, particularly in 
cardiovascular and renal cells, is an area of 
fascinating current research.
In summary, Bianchi and colleagues3 
provide convincing new evidence that 
aggressive reduction of systolic blood 
pressure and blockade of all components 
of the renin–angiotensin–aldosterone sys-
tem with the use of an aldosterone recep-
tor antagonist in addition to ACEIs and/or 
ARBs is useful in halting the progression 
of CKD. Monitoring of serum potassium, 
particularly in those with a reduced esti-
mated glomerular fi ltration rate less than 
60 ml per min per 1.73 m2, and of the other 
recognized side eff ects of the agents used, 
such as angioedema, cough, gynecomastia, 
and sexual dysfunction, is a required ele-
ment of careful follow-up.
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Asymmetric dimethylarginine in 
end-stage renal disease patients: 
A biomarker modifiable by 
calcium blockade and angiotensin 
II antagonism?
C Zoccali1
The nitric oxide synthase inhibitor asymmetric dimethylarginine 
(ADMA) is an emerging risk biomarker in  cardiovascular and renal 
diseases.  Apparently amlodipine and valsartan produce substantial 
reductions in the plasma concentration of this methylarginine in 
hemodialysis patients. These findings are of relevance for designing 
studies aimed at testing the etiologic relevance of ADMA to the high 
cardiovascular risk of ESRD.
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Cardiovascular disease and the attend-
ant risk of death and disabling compli-
cations in patients with chronic kidney 
disease are now legitimately considered 
as a major public-health problem. Th e 
astonishingly high diff erential in the risk 
of cardiovascular death between the end-
stage renal disease (ESRD) population 
and the general population cannot be 
overemphasized. Collectively, classical 
risk factors and comorbidities explain less 
than 50% of the variability in the risk of 
all-cause and cardiovascular mortality in 
this condition.1 For this reason, research 
on new cardiovascular risk factors and 
markers in patients with renal diseases 
is fl ourishing and also attracts investiga-
tors exterior to the realm of nephrology. 
Among new and emerging risk factors in 
ESRD, the nitric oxide synthase inhibitor 
asymmetric dimethylarginine (ADMA) 
has progressively gained center stage. 
Notwithstanding that this biomarker 
was tested just in one prospective cohort 
study,2 it is considered not only as an 
intriguing predictor of death and cardio-
vascular events but also as a likely causa-
tive factor of cardiovascular damage in 
this population. Interest in ADMA stems 
mainly from the fact that this compound 
perturbs a variety of physiologic functions 
that are notoriously altered in uremia 
(reviewed by Kielstein and Zoccali3).
Asymmetric dimethylarginine as a 
uremic toxin
ADMA has clear-cut cardiovascular 
eff ects in vivo in humans, and it appears 
likely that this methylarginine participates 
in the regulation of vascular tone.4 What 
makes ADMA almost unique among 
emerging cardiovascular risk factors 
is that this substance fulfi ls the criteria 
for being formally considered a uremic 
toxin.3 Cutting-edge studies by Kielstein et 
al. have nicely shown that in humans the 
administration of a sub-pressor dose of 
ADMA determines a 15% decrease in cer-
ebral perfusion.5 ADMA interferes with 
several hormonal systems; it is altered in 
clinical and subclinical hypothyroidism 
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and in insulin-resistant states and impli-
cated in bone disease, at least in experi-
mental models. Furthermore, it may be 
implicated in impotence as well as in 
male and female infertility. Notably, this 
substance may have far-reaching eff ects 
on vascular biology, because in vitro it 
shortens telomere length by activating 
telomerase and because it may hinder re-
endothelialization of damaged vessels.3
How can asymmetric dimethylarginine 
be reduced?
ADMA is a low-molecular weight toxin. 
Yet neither hemodialysis nor peritoneal 
dialysis is an eff ective means for remov-
ing ADMA. The main biologic action 
of ADMA is inhibition of nitric oxide 
synthesis. In theory, such an inhibition 
can be overcome by administration of 
high doses of the parent amino acid, 
l-arginine, which is the most abundant 
substrate to nitric oxide synthase. l-
arginine administered as a chloride salt, 
that is, in a form that produces acidosis, 
was ineff ective in reducing proteinuria in 
patients with chronic kidney disease and 
failed to improve endothelial function in 
children with chronic kidney disease.4 
Although the issue still deserves to be 
properly investigated, it seems unlikely 
that countering ADMA only with high 
doses of l-arginine is an appropriate inter-
vention to limit the cardiovasculo-toxic 
eff ects of this compound. ADMA may 
exert eff ects independent of nitric oxide 
inhibition, and it cannot be excluded a 
priori that these eff ects are pathophysi-
ologically relevant. Th us pharmacologic 
manipulation of ADMA biosynthesis 
and/or degradation seems necessary if 
we are to set up clinical trials aimed at 
establishing whether or not ADMA is a 
modifi able risk factor in ESRD patients.
Methylarginines are continuously pro-
duced during normal protein turnover. 
Th e symmetric enantiomer of ADMA, 
symmetric dimethylarginine (SDMA), is 
predominantly disposed of by the renal 
route (about 60%), whereas only 5% of 
intravenously injected ADMA is recov-
ered in the urine. For this reason, plasma 
SDMA in ESRD patients is two to three 
times higher than ADMA. Degradation 
by the enzyme dimethylarginine dimethyl-
aminohydrolase (DDAH) is a primary 
regulator of ADMA levels (Figure 1), 
whereas SDMA is not a substrate for 
DDAH. Experimental DDAH inhibition 
in vitro induces gradual vasoconstriction 
of isolated vascular segments, which may 
be reversed by addition of l-arginine to 
the medium. Th is phenomenon implies 
that ADMA is constantly being produced 
in the course of protein degradation. A 
variety of factors that engender oxidative 
stress, including hypercholesterolemia, 
hyperglycemia, and smoking, inhibit 
DDAH activity and raise plasma ADMA,4 
and in some experimental settings the 
eff ects of oxidative stress on DDAH activ-
ity can be prevented by the use of anti-
oxidants. Yet the observation that almost 
all randomized controlled trials based on 
antioxidants performed so far have failed 
to produce sensible clinical benefi ts makes 
it unlikely that reduction of ADMA levels 
by antioxidants might be translated into 
a measurable reduction in cardiovascular 
risk. Peroxisome proliferator-activated 
receptor-γ agonists such as rosiglitazone 
are among the strongest ADMA modi-
fi ers.4 Peroxisome proliferator-activated 
receptor-γ agonists may cause salt reten-
tion, which is a limitation for testing the 
eff ect of these drugs in chronic kidney dis-
ease patients, but in theory such a limita-
tion does not apply to the vast majority 
of ESRD patients, who are functionally 
anephric. In general, angiotensin-convert-
ing enzyme inhibitors and angiotensin II 
receptor blockers produce modest but 
signifi cant reductions in plasma ADMA 
in non-uremic patients.4 Telmisartan, 
an angiotensin II blocker with a peculiar 
peroxisome proliferator-activated recep-
tor-γ agonist property, seems of particular 
interest in this respect.6
New and future interventions that can 
modify asymmetric dimethylarginine
Aslam and colleagues7 (this issue) report 
that amlodipine and valsartan cause a 
relevant reduction (~40%) in plasma 
ADMA and SDMA levels while arterial 
pressure is being kept at a fixed level. 
Although substantial, the biochemical 
eff ect of these drugs did not normalize 
plasma ADMA and SDMA levels, which 
remained two to three times higher 
than normal. Interestingly, the decline 
in plasma methylarginines was accom-
panied by a parallel decrease in oxida-
tive stress markers. The parallelism 
between ADMA changes and oxidative 
stress biomarker changes in the face of 
unmodifi ed blood pressure would point 
to oxidative stress as a likely underlying 
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Figure 1 | Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are 
continuously generated during protein turnover. The primary source of these methylarginines 
are nucleolar proteins. Protein arginine methyltransferases (PRMTs) methylate these proteins, and 
ADMA and SDMA are then generated by hydrolysis. The bulk of ADMA (80%) is degraded by the 
enzyme dimethylarginine dimethylaminohydrolase (DDAH), and the remaining 20% is eliminated 
by the renal route. SDMA is mainly excreted in the urine, and it is not degraded by DDAH.
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mechanism. However, DDAH inhi-
bition would be expected to reduce 
ADMA but not SDMA levels. In this 
context it is legitimate to hypothesize 
that amlodipine and valsartan interfere 
with the synthesis rather than with the 
degradation of methylarginines (Figure 
1). In other words, these drugs may blunt 
the activity of the enzyme that synthe-
sizes methylarginines, that is, protein 
arginine methyltransferases. Shear stress 
increases ADMA by activating protein 
arginine methyltransferases,8 and the 
parallel fall in plasma levels of methyl-
arginines with two potent antihyper-
tensive drugs would prima facie suggest 
blood pressure-dependent mechanisms, 
which was not the case, since, because 
of concomitant changes introduced into 
the antihypertensive regimen, blood 
pressure was kept almost unmodifi ed. 
Intriguingly, the marked eff ect on cir-
culating methylarginines of amlodipine 
and valsartan was also largely dissociated 
from C-reactive protein changes, which 
contrasts with findings in stage 1–2 
hypertensives,9 in whom valsartan has a 
measurable, blood pressure-independent, 
anti-infl ammatory eff ect. Overall, Aslam 
et al.7 report stimulating, thought-pro-
voking fi ndings, but the experimental 
maneuver they adopted — that is, with-
drawing other antihypertensive drugs 
while introducing the test drugs — is 
fairly complex and open to confounding. 
External validation of the observations 
in this study and other experimental 
approaches to the problem seem war-
ranted to establish these drugs as suitable 
ADMA modifi ers in ESRD patients.
There is a paucity of clinical trials 
aimed at testing whether and how the 
high cardiovascular risk of ESRD can be 
reduced. Th e few randomized control-
led studies performed until now are not 
so heartening. The Deutsche Diabetes 
Dialysis study showed that it is unlikely 
that statins produce major eff ects on the 
high mortality in this condition, and there 
is evidence that the benefi ts associated 
with higher hemoglobin targets may be 
outweighed by an increased risk of hyper-
tension and death. Furthermore, there is 
still no proof that control of hyperphos-
phatemia improves survival. In this sce-
nario, angiotensin II receptor blockers 
stand as a promising therapeutic avenue, 
because there is fresh evidence that tel-
misartan added to other drugs, including 
angiotensin-converting enzyme inhibi-
tors, reduces all-cause and cardiovascu-
lar mortality in hemodialysis patients with 
heart failure (G Cice et al., Nephrol Dial 
Transplant 2005; 20(Suppl 5): v187, abstr.), 
the patient category at highest risk in the 
ESRD population. Th e fact that this drug 
has the potential to lower ADMA, and the 
observations by Aslam et al. with valsar-
tan,7 constitute further circumstantial evi-
dence supporting the view that countering 
ADMA may be a relevant, worthy area of 
intervention. Observational studies based 
on the United States Renal Data System 
database show better clinical outcomes 
in ESRD patients treated with calcium-
channel blockers than in patients treated 
with other antihypertensive drugs. If con-
fi rmed, the eff ect of amlodipine unraveled 
in the study by Aslam et al.7 may be a 
clue for the interpretation of the putative 
cardiovasculo-protective eff ect of calcium-
channel blockers in this population.
Studies of high-resolution crystal struc-
tures of DDAH isoforms are giving insight 
into the molecular mechanisms that 
regulate this enzyme. In the near future 
the fabrication of DDAH activators will 
hopefully allow testing of whether ADMA 
normalization improves clinical outcomes 
in a situation of uniquely high cardiovas-
cular risk such as ESRD.
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